11β-Hydroxyandrostenedione and δ5-androstenediol as markers of adrenal androgen production in patients with 21-hydroxylase-deficient nonclassic adrenal hyperplasia

Raquel Huerta, Didier Dewailly, Christine Decanter, Eric S. Knochenhauer, Larry R. Boots, Ricardo Azziz

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: To determine the sensitivity of 11β-hydroxyandrostenedione (11-OHA4) and Δ5-androstenediol (ADIOL) as markers of excessive adrenal androgen production. Design: Prospective study. Setting: Academic medical centers. Patient(s): Thirteen women with untreated 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH) and 18 healthy, eumenorrheic, nonhirsute controls matched for age and body mass index. Intervention(s): All subjects were studied before and after acute adrenal stimulation with 0.25 mg of IV ACTH-(1-24). Main Outcome Measure(s): Basal levels of total testosterone, sex hormone-binding globulin, DHEAS, and free testosterone were measured. Levels of androstenedione (A4), DHEA, 11-OHA4, and ADIOL were determined before (Steroid0) and 60 minutes after (Steroid60) acute ACTH- (1-24) stimulation. Result(s): Patients with NCAH had higher median basal levels of DHEAS and total and free testosterone than controls. Patients with NCAH had higher median A40, A460, DHEA0, DHEA60, 11-OHA40, ADIOL0, and ADIOL60 levels but similar 11-OHA460 levels compared with controls. Among patients with NCAH, 30%, 54%, 15%, and 85% had 11-OHA40, ADIOL0, 11- OHA460, and ADIOL60 levels, respectively, above the 95th percentile of controls. Conclusion(s): Overall, serum levels of 11-OHA4 did not appear to be a very sensitive marker of excessive adrenal androgen production, at least in patients with NCAH. Although ACTH-stimulated ADIOL levels were elevated in 85% of the patients studied, they did not appear to have any advantage over the measurement of A4 or DHEA levels.

Original languageEnglish (US)
Pages (from-to)996-1000
Number of pages5
JournalFertility and sterility
Volume72
Issue number6
DOIs
StatePublished - Dec 1 1999

Fingerprint

Androstenediol
Steroid 21-Hydroxylase
Androgens
Hyperplasia
Cosyntropin
Testosterone
Dehydroepiandrosterone
Sex Hormone-Binding Globulin
Androstenedione
Adrenocorticotropic Hormone
11-hydroxyandrostenedione
Body Mass Index
Outcome Assessment (Health Care)
Prospective Studies
Serum

Keywords

  • 11β-Hydroxyandrostenedione
  • 21- hydroxylase
  • Nonclassic adrenal hyperplasia
  • Δ-androstenediol

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

11β-Hydroxyandrostenedione and δ5-androstenediol as markers of adrenal androgen production in patients with 21-hydroxylase-deficient nonclassic adrenal hyperplasia. / Huerta, Raquel; Dewailly, Didier; Decanter, Christine; Knochenhauer, Eric S.; Boots, Larry R.; Azziz, Ricardo.

In: Fertility and sterility, Vol. 72, No. 6, 01.12.1999, p. 996-1000.

Research output: Contribution to journalArticle

Huerta, Raquel ; Dewailly, Didier ; Decanter, Christine ; Knochenhauer, Eric S. ; Boots, Larry R. ; Azziz, Ricardo. / 11β-Hydroxyandrostenedione and δ5-androstenediol as markers of adrenal androgen production in patients with 21-hydroxylase-deficient nonclassic adrenal hyperplasia. In: Fertility and sterility. 1999 ; Vol. 72, No. 6. pp. 996-1000.
@article{f33b38f3b3d6445598eed3646b77a02c,
title = "11β-Hydroxyandrostenedione and δ5-androstenediol as markers of adrenal androgen production in patients with 21-hydroxylase-deficient nonclassic adrenal hyperplasia",
abstract = "Objective: To determine the sensitivity of 11β-hydroxyandrostenedione (11-OHA4) and Δ5-androstenediol (ADIOL) as markers of excessive adrenal androgen production. Design: Prospective study. Setting: Academic medical centers. Patient(s): Thirteen women with untreated 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH) and 18 healthy, eumenorrheic, nonhirsute controls matched for age and body mass index. Intervention(s): All subjects were studied before and after acute adrenal stimulation with 0.25 mg of IV ACTH-(1-24). Main Outcome Measure(s): Basal levels of total testosterone, sex hormone-binding globulin, DHEAS, and free testosterone were measured. Levels of androstenedione (A4), DHEA, 11-OHA4, and ADIOL were determined before (Steroid0) and 60 minutes after (Steroid60) acute ACTH- (1-24) stimulation. Result(s): Patients with NCAH had higher median basal levels of DHEAS and total and free testosterone than controls. Patients with NCAH had higher median A40, A460, DHEA0, DHEA60, 11-OHA40, ADIOL0, and ADIOL60 levels but similar 11-OHA460 levels compared with controls. Among patients with NCAH, 30{\%}, 54{\%}, 15{\%}, and 85{\%} had 11-OHA40, ADIOL0, 11- OHA460, and ADIOL60 levels, respectively, above the 95th percentile of controls. Conclusion(s): Overall, serum levels of 11-OHA4 did not appear to be a very sensitive marker of excessive adrenal androgen production, at least in patients with NCAH. Although ACTH-stimulated ADIOL levels were elevated in 85{\%} of the patients studied, they did not appear to have any advantage over the measurement of A4 or DHEA levels.",
keywords = "11β-Hydroxyandrostenedione, 21- hydroxylase, Nonclassic adrenal hyperplasia, Δ-androstenediol",
author = "Raquel Huerta and Didier Dewailly and Christine Decanter and Knochenhauer, {Eric S.} and Boots, {Larry R.} and Ricardo Azziz",
year = "1999",
month = "12",
day = "1",
doi = "10.1016/S0015-0282(99)00402-1",
language = "English (US)",
volume = "72",
pages = "996--1000",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - 11β-Hydroxyandrostenedione and δ5-androstenediol as markers of adrenal androgen production in patients with 21-hydroxylase-deficient nonclassic adrenal hyperplasia

AU - Huerta, Raquel

AU - Dewailly, Didier

AU - Decanter, Christine

AU - Knochenhauer, Eric S.

AU - Boots, Larry R.

AU - Azziz, Ricardo

PY - 1999/12/1

Y1 - 1999/12/1

N2 - Objective: To determine the sensitivity of 11β-hydroxyandrostenedione (11-OHA4) and Δ5-androstenediol (ADIOL) as markers of excessive adrenal androgen production. Design: Prospective study. Setting: Academic medical centers. Patient(s): Thirteen women with untreated 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH) and 18 healthy, eumenorrheic, nonhirsute controls matched for age and body mass index. Intervention(s): All subjects were studied before and after acute adrenal stimulation with 0.25 mg of IV ACTH-(1-24). Main Outcome Measure(s): Basal levels of total testosterone, sex hormone-binding globulin, DHEAS, and free testosterone were measured. Levels of androstenedione (A4), DHEA, 11-OHA4, and ADIOL were determined before (Steroid0) and 60 minutes after (Steroid60) acute ACTH- (1-24) stimulation. Result(s): Patients with NCAH had higher median basal levels of DHEAS and total and free testosterone than controls. Patients with NCAH had higher median A40, A460, DHEA0, DHEA60, 11-OHA40, ADIOL0, and ADIOL60 levels but similar 11-OHA460 levels compared with controls. Among patients with NCAH, 30%, 54%, 15%, and 85% had 11-OHA40, ADIOL0, 11- OHA460, and ADIOL60 levels, respectively, above the 95th percentile of controls. Conclusion(s): Overall, serum levels of 11-OHA4 did not appear to be a very sensitive marker of excessive adrenal androgen production, at least in patients with NCAH. Although ACTH-stimulated ADIOL levels were elevated in 85% of the patients studied, they did not appear to have any advantage over the measurement of A4 or DHEA levels.

AB - Objective: To determine the sensitivity of 11β-hydroxyandrostenedione (11-OHA4) and Δ5-androstenediol (ADIOL) as markers of excessive adrenal androgen production. Design: Prospective study. Setting: Academic medical centers. Patient(s): Thirteen women with untreated 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH) and 18 healthy, eumenorrheic, nonhirsute controls matched for age and body mass index. Intervention(s): All subjects were studied before and after acute adrenal stimulation with 0.25 mg of IV ACTH-(1-24). Main Outcome Measure(s): Basal levels of total testosterone, sex hormone-binding globulin, DHEAS, and free testosterone were measured. Levels of androstenedione (A4), DHEA, 11-OHA4, and ADIOL were determined before (Steroid0) and 60 minutes after (Steroid60) acute ACTH- (1-24) stimulation. Result(s): Patients with NCAH had higher median basal levels of DHEAS and total and free testosterone than controls. Patients with NCAH had higher median A40, A460, DHEA0, DHEA60, 11-OHA40, ADIOL0, and ADIOL60 levels but similar 11-OHA460 levels compared with controls. Among patients with NCAH, 30%, 54%, 15%, and 85% had 11-OHA40, ADIOL0, 11- OHA460, and ADIOL60 levels, respectively, above the 95th percentile of controls. Conclusion(s): Overall, serum levels of 11-OHA4 did not appear to be a very sensitive marker of excessive adrenal androgen production, at least in patients with NCAH. Although ACTH-stimulated ADIOL levels were elevated in 85% of the patients studied, they did not appear to have any advantage over the measurement of A4 or DHEA levels.

KW - 11β-Hydroxyandrostenedione

KW - 21- hydroxylase

KW - Nonclassic adrenal hyperplasia

KW - Δ-androstenediol

UR - http://www.scopus.com/inward/record.url?scp=0032589566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032589566&partnerID=8YFLogxK

U2 - 10.1016/S0015-0282(99)00402-1

DO - 10.1016/S0015-0282(99)00402-1

M3 - Article

VL - 72

SP - 996

EP - 1000

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 6

ER -